TY  - JOUR
T1  - Can cognitive impairment be observed independently of neurological symptoms in Behcet's disease?
TT  - Behçet hastalığında nörolojik semptomlardan bağımsız olarak bilişsel bozukluk mevcut olabilir mi?
AU  - Karstarlı Bakay, Özge Sevil
AU  - Bakay, Umut
AU  - Bora, Pinar
PY  - 2025
DA  - January
Y2  - 2024
DO  - 10.31362/patd.1584077
JF  - Pamukkale Medical Journal
JO  - Pam Tıp Derg
PB  - Pamukkale University
WT  - DergiPark
SN  - 1308-0865
SP  - 159
EP  - 165
VL  - 18
IS  - 1
LA  - en
AB  - Purpose: Behçet's disease (BD) is a chronic, multisystem inflammatory disorder that causes mortality andmorbidity. Despite data indicating cognitive impairment in patients without neurological involvement, there iscurrently no consensus on how to screen patients. The Montreal Cognitive Assessment (MOCA) is a practical,easy-to-use screening scale that can detect mild cognitive impairment. We aimed to detect cognitive dysfunctionwith MOCA in BD without neurological findings.Materials and methods: This prospective study included patients diagnosed with BD without neurologicalfindings, and healthy individuals matched for age, gender, and education. Behçet's Disease Current ActivityForm (BDCAF) was applied to determine disease activity, and MOCA was applied to all participants.Results: The total score of the MOCA scale was significantly lower in Behçet's patients than in the control group(p=0.001). While no difference was found between BD and controls in terms of MOCA subtests ‘‘Orientation’’and ‘‘Abstraction’’ (p=0.667, p=0.077, respectively), scores in other subtests were significantly lower in patients.A negative correlation was found between BDCAF scores and total MOCA scores (r=-0.454, p=0.000). A positivecorrelation was found between total MOCA score and years of education (r=0.345, p=0.000).Conclusion: In BD, a decrease in cognitive functions may exist without neurological involvement. Cognitivescreening of patients with BD is crucial for detecting subclinical inflammation and improving quality of life. Ourresults demonstrate that the MOCA is an effective tool for detecting cognitive function decline. However, furtherlarge-scale, multi-center studies are needed to establish its routine use.
KW  - Behçet disease
KW  - cognitive impairment
KW  - montreal cognitive assessment
N2  - Amaç: Behçet hastalığı (BH) birçok sistemin etkilendiği mortalite ve morbiteye yol açan kronik inflamatuvarbir hastalıktır. BH’de nörolojik tutulum bulguları olmaksızın hastalarda bilişsel fonksiyonların etkilendiğinedair veriler olsa da bu hastaların taramasına yönelik br fikir birliğine henüz ulaşılamamıştır. Montreal BilişselDeğerlendirme (MOBİD), hafif düzeyde bilişsel fonksiyon bozuklukları tespit edebilen pratik, kolay erişilebilirbir tarama ölçeğidir. Çalışmamızda nörolojik bulguları olmayan BH’de MOBİD ile bilişsel fonksiyon bozukluklarıtespit edebilmeyi amaçladık.Gereç ve yöntem: Bu prospektif çalışmaya BH tanısı alan ve nörolojik bulgusu olmayan hastalar ile yaş, cinsiyetve eğitim açısından eşleştirilmiş sağlıklı bireyler dahil edildi. Hastalık aktitesini belirlemek için Behçet HastalığıGüncel Aktivite Formu (BDCAF) uygulanırken tüm katılımcılara MOBİD uygulandı.Bulgular: MOBİD ölçeğinin toplam puanı Behçet hastalarında kontrol grubuna göre belirgin olarak düşüktü(p<0.05). MOBİD alt testlerinden ‘‘Yönelim’’ ve ‘‘Soyutlama’’ açısından BH ve kontroller arasında farksaptanmamışken (p>0.05) diğer alt testlerde puan hastalarda anlamlı olarak düşüktü (p<0.05). BDCAFskorlarıyla toplam MOBİD puanı arasında negatif korelasyon saptandı (r=-0.43, p<0.001). Total MOBİD puanıile eğitim yılı arasında pozitif korelasyon saptandı (r=0.35, p=0.007).Sonuç: BH’de nörolojik tutulum olmaksızın bilişsel fonksiyonlarda azalma mümkündür. BH’de hastaların bilişselaçıdan taranması subklinik inflmasyonun tespit edilmesi ve yaşam kalitesinin iyileştirilmesi için önemlidir.Sonuçlarımız, MOBİD tarama ölçeği ile bilişsel fonksiyonlardaki azalma pratik bir şekilde saptanabileceğinigöstermiş olsa da rutin kullanıma girmesi için geniş çaplı, çok merkezli çalışmalara ihtiyaç vardır.
CR  - Saadoun D, Bodaghi B, Cacoub P. Behçet's syndrome. N Engl J Med. 2024;390(7):640-651. doi:10.1056/NEJMra2305712
CR  - Alpsoy E, Bozca BC, Bilgic A. Behçet disease: An update for dermatologist. Am J Clin Dermatol. 2021;22:477-502. doi:10.1007/s40257-021-00609-4
CR  - Siva A, Saip S. The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. J Neurol. 2009;256:513-529. doi:10.1007/s00415-009-0145-6
CR  - Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803-806. doi:10.1046/j.1365-4362.2003.01893.x
CR  - Caruso P, Moretti R. Focus on neuro-Behçet's disease: A review. Neurol India. 2018;66(6):1619-1628. doi:10.4103/0028-3886.246252
CR  - Borhani Haghighi A, Kardeh B, Banerjee S, et al. Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord. 2020;39:101906. doi:10.1016/j.msard.2019.101906
CR  - Fisher CA. Psychological and neurocognitive impact of Behcet’s disease. Int J Vasc Surg Med. 2020;6:1-8. doi:10.31487/j.NNB.2020.01.05
CR  - Kidd DP. Neurological complications of Behçet's syndrome. J Neurol. 2017;264(10):2178-2183. doi:10.1007/s00415-017-8436-9
CR  - Fisher CA, Bernard C. A systematic review of neurocognitive functioning in Behçet’s disease. Neuropsychol Rev. 2019;29:498-521. doi:10.1007/s11065-019-09416-5
CR  - Monastero R, Camarda C, Pipia C, et al. Cognitive impairment in Behçet’s disease patients without overt neurological involvement. J Neurol Sci. 2004;220:99-104. doi:10.1016/j.jns.2004.02.021
CR  - Özen E, Birol A, Boratav C, Koçak M. Nörolojik tutulumu olmayan Behçet hastalarında bilişsel bozukluklar. Klinik Psikiyatri Dergisi. 2004;7(4):187-198.
CR  - Sucullu Karadag Y, Kurt P, Sahin K, Karaaslan Y, Oztekin N, Ak F. Cognitive impairment not only in NeuroBehçet but also for all Behçet disease phenotypes. Journal of Neurological Sciences. 2014;31(3):511-520.
CR  - Dutra LA, de Souza AW, Alessi H, et al. Cognitive impairment in Brazilian patients with Behçet's disease occurs independently of neurologic manifestation. J Neurol Sci. 2013;327:1-5. doi:10.1016/j.jns.2013.01.024
CR  - Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699. doi:10.1111/j.1532-5415.2005.53221.x
CR  - Ozdilek B, Kenangil G. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease. Clin Neuropsychol. 2014;28(2):333-343. doi:10.1080/13854046.2014.881554
CR  - Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597.
CR  - Neves FS, Moraes JC, Kowalski SC, Goldenstein Schainberg C, Lage LV, Gonçalves CR. Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol. 2008;26:1263-1267. doi:10.1007/s10067-006-0484-y
CR  - Selekler K, Cangöz B, Uluç S. Power of Discrimination of Montreal Cognitive Assessment (MOCA) Scale in Turkish Patients with Mild Cognitive Impairment and Alzheimer's Disease. Turkish Journal of Geriatrics. 2010;13:166-171.
CR  - Tunç T, Ortapamuk H, Naldöken S, et al. Subclinical neurological involvement in Behcet’s disease. Neurol India. 2006;54:408-411. doi:10.4103/0028-3886.28116
CR  - Kececi HM, Akyol P. 300 in Behcet’s patients without neurological manifestations. Can J Neurol Sci. 2001;28:66-69. doi:10.1017/s0317167100052586
CR  - Anlar O, Akdeniz N, Tombul T, Calka O, Bilgili SG. Visual evoked potential findings in Behcet’s disease without neurological manifestations. Intern J Neuroscience. 2006;116:281-287. doi:10.1080/00207450500403165
CR  - Ozisik HI, Karlidag R, Hazneci E, Kizkin S, Ozcan C. Cognitive event-related potential and neuropsychological findings in Behçet's disease without neurological manifestations. Tohoku J Exp Med. 2005;206:15-22. doi:10.1620/tjem.206.15.
CR  - Cavaco S, da Silva AM, Pinto P, et al. Cognitive functioning in Behcet's disease. Ann N Y Acad Sci. 2009;1173:217-226. doi:10.1111/j.1749-6632.2009.04670.x
CR  - Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: A systematic review and meta-analysis. Psychol Med. 2014;44:2029-2040. doi:10.1017/S0033291713002535
CR  - Goodall J, Fisher C, Hetrick S, Phillips L, Parrish EM, Allott K. Neurocognitive Functioning in Depressed Young People: A Systematic Review and Meta-Analysis. Neuropsychol Rev. 2018;28:216-231. doi:10.1007/s11065-018-9373-9
CR  - Castaneda AE, Tuulio Henriksson A, Marttunen M, Suvisaari J, Lönnqvist J. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J Affect Disord. 2008;106:1-27. doi:10.1016/j.jad.2007.06.006
CR  - Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: A dose–response study in humans. Behav Neurosci. 1999;113:420-430. doi:10.1037//0735-7044.113.3.420
CR  - Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion. J Clin Psychiatry. 2001;3(1):17-21. doi:10.4088/pcc.v03n0104
CR  - Khoshbakht S, Başkurt D, Vural A, Vural S. Behçet's Disease: A Comprehensive Review on the Role of HLA-B*51, Antigen Presentation, and Inflammatory Cascade. Int J Mol Sci. 2023;24:16382. doi:10.3390/ijms242216382
CR  - Al Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192-204. doi:10.1016/S1474-4422(09)70015-8
CR  - Papastefanakis E, Dimitraki G, Ktistaki G, et al. Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample. Lupus. 2021;30(14):2237-2247. doi:10.1177/09612033211061062
CR  - Paez Venegas N, Jordan Estrada B, Chavarria Avila E, et al. The Montreal cognitive assessment test: a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus. J Clin Rheumatol. 2019;25:325-328. doi:10.1097/RHU.0000000000000876
CR  - Nantes SG, Su J, Dhaliwal A, et al. Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2017;44:1583-1589. doi:10.3899/jrheum.161125
CR  - Adhikari T, Piatti A, Luggen M. Cognitive dysfunction in SLE: development of a screening tool. Lupus. 2011;20:1142-1146. doi:10.1177/0961203311405374
UR  - https://doi.org/10.31362/patd.1584077
L1  - https://dergipark.org.tr/en/download/article-file/4361180
ER  -